Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with...

Area of Science:

• Oncology
• Pharmacology

Background:

• Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) represent a significant advancement in treating advanced EGFR-mutant non-small cell lung cancer (NSCLC).
• They effectively address acquired T790M resistance mutations that limit the efficacy of earlier TKIs.
• The role of these agents in T790M-negative or unknown NSCLC populations, especially those with brain metastases, is an area of active investigation.

Purpose of the Study:

• To review the current evidence and expert consensus on the use of third-generation EGFR-TKIs in advanced NSCLC.
• To highlight their efficacy in overcoming resistance and their potential in T790M-negative or unknown NSCLC, including patients with brain metastases.
• To identify the need for further prospective research to fully define their therapeutic role.

Main Methods:

• Expert consensus review of existing studies and clinical data.
• Analysis of efficacy data for third-generation EGFR-TKIs (osimertinib, aumolertinib) in various NSCLC patient populations.
• Focus on outcomes in T790M-positive, T790M-negative, and T790M-unknown NSCLC, with specific attention to brain metastases.

Main Results:

• Third-generation EGFR-TKIs are effective against acquired T790M mutations in advanced NSCLC.
• These agents demonstrate potential benefits in T790M-negative or unknown NSCLC, including significant control of intracranial lesions in patients with brain metastases.
• High blood-brain barrier permeability contributes to their efficacy in central nervous system disease.

Conclusions:

• Third-generation EGFR-TKIs are crucial in managing advanced NSCLC, particularly in overcoming resistance.
• Their utility extends to T790M-negative or unknown NSCLC, offering new therapeutic avenues, especially for patients with brain metastases.
• Further prospective trials are essential to comprehensively understand the efficacy of these agents in diverse NSCLC patient groups post-TKI failure.